Psilera and USF Collaborators at Morsani College of Medicine Receive Additional Funding to Support Preclinical Studies of Novel Chemical Entities


The Florida High Tech Corridor has matched Psilera’s contribution to research focused on developing new DMT derivatives with non-hallucinogenic properties for mental health and addiction disorders

TAMPA, Florida., March 8, 2022 /PRNewswire/ — Psilera Inc. (“Psilera”)a biotechnology company specializing in the clinical development of psychedelic-inspired compounds and drug delivery systems for the treatment of mental health disorders, has secured over $130,000 from the Florida High Tech Corridor’s Matching Grants Research Program, effectively doubling the duration of a study conducted in collaboration with researchers from the University of South Florida (“USF”). This preclinical study focuses on understanding the non-hallucinogenic properties of Psilera N,N-dimethyltryptamine (DMT) derivatives and their therapeutic potential for treating mood and addiction disorders.


Psilera’s research team identified lead candidates from its patent-pending drug library, aided by its proprietary virtual data platform, and synthesized these compounds for crucial biological assays. The funded study, “Development of new N,N-Dialkyltryptamines for the Treatment of Mental Health and Alcohol Use Disorders,” will be led by Dr. Danielle GulickAssistant Professor, Department of Molecular Medicine, USF Health Morsani College of Medicine, and supported by USF Health Student Researchers.

“We are proud to support Psilera’s continued collaboration with USF’s Morsani College of Medicine as they deliver on their commitment to grow in our region,” said Corridor’s CEO. Paul A.Sohl, Rear Adm. USN (ret). “Our matching funds provide a tangible benefit to Psilera and allow USF students to apply the skills they learn in the classroom to solve real-world problems and gain valuable insights as they enter our region’s high-tech workforce.”

Previously, Psilera announced that its first DMT derivative, PSIL-002, did not induce hallucinogenic effects in mice at extremely high doses above 100 mg/kg. PSIL-002 can therefore have 10 times the dose flexibility of moderate hallucinogens like DMT and psilocybin. Psilera confirmed that PSIL-002 can access and impact brain regions critical to mental health, including the prefrontal cortex, amygdala, and limbic system. Other behavioral studies focusing on antidepressant, anxiolytic, and cognitive effects have shown promising efficacy, with memory and learning having the greatest increase for PSIL-002. A second DMT analog, PSIL-001, is currently undergoing the same preclinical testing.

“At Psilera, we strive to design cutting-edge mental health therapies that avoid the negative side effects often reported with anti-anxiety medications, antidepressants, and similar mood-stabilizing pharmaceuticals,” said Dr. Jackie Von Salmco-founder and chief scientific officer of Psilera Inc. “This generous show of support and trust from The Corridor and USF allows us to accelerate our research to discover next-generation drugs for devastating mental health issues.”

About Psilera Inc.
Psilera is a leading biotechnology company developing proprietary neuromodulators based on traditionally psychoactive compounds targeting mental health disorders. Psilera’s next-generation data platform is used to identify lead compounds with altered psychedelic and therapeutic effects in mood, cognitive and substance use disorders. New formulations adapting the therapeutic effects of DMT will improve treatment scalability and patient compliance, further expanding addressable markets. Psilera relies on a world-class scientific and pharmaceutical leadership team to transform psychoactive natural products into effective and accessible patient-centered treatments.

About Florida High-Tech Corridor
An economic development initiative of three research universities – the University of Central Floridathe University of South Florida and the University of Florida – the Florida High Tech Corridor converges and catalyzes the capacity of high technology, innovation and bright minds in a 23-county region to generate a global ripple effect that improves the lives of people in the communities it serves dessert. Powered by a philosophy of collaboration, The Corridor aligns opportunities and resources in academia, industry, and economic development to unlock the “potential” of the region.

Media Contact: Katie DeMarsh[email protected]



View original content to download multimedia: -preclinical-studies-on-new-chemical-entities-301497847.html

SOURCEPsilera, Inc


Comments are closed.